aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
aTyr Pharma (Nasdaq: ATYR), a clinical stage biotechnology company focused on developing first-in-class medicines from its tRNA synthetase platform, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement and corporate update for March 13, 2025, after market close.
The company will host a conference call and webcast at 5:00 PM EDT / 2:00 PM PDT on the same day. Participants can join via telephone by registering through the provided dial-in link to receive their personalized PIN code, or attend the live webcast through the company's investor events page.
aTyr Pharma (Nasdaq: ATYR), una società biotecnologica in fase clinica focalizzata sullo sviluppo di farmaci innovativi dalla sua piattaforma di sintasi tRNA, ha programmato l'annuncio dei risultati finanziari del Quarto Trimestre e dell'Anno Intero 2024 e un aggiornamento aziendale per il 13 Marzo 2025, dopo la chiusura del mercato.
La società ospiterà una conferenza telefonica e un webcast alle 5:00 PM EDT / 2:00 PM PDT dello stesso giorno. I partecipanti possono unirsi telefonicamente registrandosi tramite il link fornito per ricevere il proprio codice PIN personalizzato, oppure partecipare al webcast dal vivo attraverso la pagina degli eventi per investitori della società.
aTyr Pharma (Nasdaq: ATYR), una compañía biotecnológica en etapa clínica centrada en el desarrollo de medicamentos de primera clase a partir de su plataforma de sintasa de tRNA, ha programado el anuncio de sus resultados financieros del Cuarto Trimestre y del Año Completo 2024 y una actualización corporativa para el 13 de Marzo de 2025, después del cierre del mercado.
La compañía llevará a cabo una conferencia telefónica y una transmisión en vivo a las 5:00 PM EDT / 2:00 PM PDT el mismo día. Los participantes pueden unirse por teléfono registrándose a través del enlace de acceso proporcionado para recibir su código PIN personalizado, o asistir a la transmisión en vivo a través de la página de eventos para inversores de la compañía.
aTyr Pharma (Nasdaq: ATYR)는 tRNA 합성효소 플랫폼을 기반으로 최초의 혁신적인 의약품 개발에 주력하는 임상 단계 생명공학 회사로, 2024년 4분기 및 연간 재무 결과 발표와 기업 업데이트를 2025년 3월 13일에 시장 종료 후로 예정했습니다.
회사는 같은 날 오후 5시 EDT / 오후 2시 PDT에 전화 회의 및 웹캐스트를 개최할 예정입니다. 참가자는 제공된 다이얼인 링크를 통해 등록하여 개인화된 PIN 코드를 받을 수 있으며, 회사의 투자자 이벤트 페이지를 통해 라이브 웹캐스트에 참석할 수 있습니다.
aTyr Pharma (Nasdaq: ATYR), une entreprise de biotechnologie en phase clinique axée sur le développement de médicaments de première classe à partir de sa plateforme de synthétase tRNA, a programmé l'annonce de ses résultats financiers pour le quatrième trimestre et l'année complète 2024 ainsi qu'une mise à jour de l'entreprise pour le 13 mars 2025, après la fermeture du marché.
L'entreprise organisera une conférence téléphonique et un webinaire le même jour à 17h00 EDT / 14h00 PDT. Les participants peuvent rejoindre par téléphone en s'inscrivant via le lien d'accès fourni pour recevoir leur code PIN personnalisé, ou assister au webinaire en direct via la page des événements pour investisseurs de l'entreprise.
aTyr Pharma (Nasdaq: ATYR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Arzneimitteln der ersten Klasse aus seiner tRNA-Synthetase-Plattform konzentriert, hat die Bekanntgabe seiner finanziellen Ergebnisse für das 4. Quartal und das Gesamtjahr 2024 sowie ein Unternehmensupdate für den 13. März 2025 nach Börsenschluss angesetzt.
Das Unternehmen wird am selben Tag um 17:00 Uhr EDT / 14:00 Uhr PDT eine Telefonkonferenz und einen Webcast veranstalten. Teilnehmer können sich telefonisch über den bereitgestellten Einwahllink registrieren, um ihren persönlichen PIN-Code zu erhalten, oder an dem Live-Webcast über die Investorenseite des Unternehmens teilnehmen.
- None.
- None.
Management to host conference call and webcast on March 13th at 5:00 pm EDT / 2:00 pm PDT
SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2024 financial results and provide a corporate update after the market close on Thursday, March 13, 2025. Management will host a conference call and webcast to review the results and provide an operational update.
Conference Call and Webcast Details:
Date: Thursday, March 13, 2025
Time: 5:00 p.m. EDT / 2:00 p.m. PDT
Dial-In Registration: https://register.vevent.com/register/BI00725a32705e4ee3b22d05bdd3fc4c10
Webcast Registration: http://investors.atyrpharma.com/events-and-webcasts
Participants who wish to join the conference call by telephone must register at the above dial-in registration link in order to receive the dial-in number and a personalized PIN code that will be required to access the call. Participants may join the live webcast by accessing it at the above webcast registration link on the aTyr Events page. For more information or questions, please contact aTyr’s investor relations team at investorrelations@atyrpharma.com.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Contact:
Ashlee Dunston
Sr. Director, Investor Relations and Public Affairs
adunston@atyrpharma.com
FAQ
When will aTyr Pharma (ATYR) release its Q4 and full year 2024 earnings?
How can investors join aTyr Pharma's Q4 2024 earnings call?
What time is aTyr Pharma's Q4 2024 earnings call?
What is aTyr Pharma's main business focus?
